yahE Antibody

What are the key approaches for designing antibodies with customized specificity profiles?

Recent advances in antibody design have shifted from traditional affinity-based selection methods to more sophisticated computational approaches. According to research published in 2024, biophysics-informed modeling combined with high-throughput sequencing offers significant advantages over traditional library screening .

Methodological approach:

• Identify different binding modes associated with particular ligands through experimental selection data

• Build computational models that disentangle these binding modes, even for chemically similar ligands

• Use these models to predict and generate specific variants beyond those observed experimentally

The effectiveness of this approach was demonstrated in a series of phage display experiments where antibodies were selected against various combinations of closely related ligands. The computational model successfully predicted outcomes for different ligand combinations and generated novel antibody variants with custom specificity profiles .

For researchers designing experiments to create antibodies with controlled specificity:

How can researchers assess and predict the immunogenicity potential of engineered antibodies?

Engineered antibodies containing artificial amino acid sequences can potentially be highly immunogenic, which affects both efficacy and safety. Recent research has developed rapid in vitro methods to assess immunogenicity during development.

Methodological approach:
A peripheral blood mononuclear cell-based assay can assess immunogenicity potential within 3 days by examining:

• Frequency of interleukin (IL)-2-secreting CD4+ T cells induced by therapeutic antibodies

• Proliferative activity and expression of cytokines by these T cells

This method has demonstrated correlation with clinical anti-drug antibody (ADA) incidences. For example, when seven antibodies with known rates of clinical immunogenicity were tested, the percentage of donors responding correlated closely with clinical ADA incidences: etanercept (1.9%), emicizumab (3.8%), abciximab (6.4%), romosozumab (10.0%), blosozumab (29.2%), humanized anti-human A33 antibody (43.8%), and bococizumab (89.5%) .

What are the most reliable methods for measuring antibody neutralizing activity, and how interchangeable are different assay platforms?

Multiple assay platforms exist for measuring antibody activity, but their interchangeability has been questioned. Recent research evaluating anti-SARS-CoV-2 monoclonal antibodies has provided important insights.

Methodological findings:
A comprehensive study assessed five anti-SARS-CoV-2 monoclonal antibodies using:

• ELISA (enzyme-linked immunosorbent assay)

• Surface plasmon resonance (SPR)

• Four different cell-based neutralization assays using different pseudovirus particles and cell lines

The analysis revealed that IC50 values determined by different neutralization assays were largely independent of:

• The cell line used (293T vs. A549)

• Presence of TMPRSS2 enzyme on the cell surface

• Pseudovirus backbone used (LV or MLV)

Bland-Altman analysis showed that the IC50 (neutralization) and KD (binding) values determined by different methods were essentially equivalent, with bias between assays ranging from -0.3 nM to +1.6 nM at a 95% confidence interval .

Significantly, the data indicated that anti-spike monoclonal antibody activity can be primarily attributed to one variable directly related to tertiary conformational structure: the rate dissociation constant (Koff). This parameter is independent of component concentrations in the mAb:RBD:hACE2 complexes .

Note for researchers: This interchangeability appears most reliable when using high-affinity antibodies (KD~IC50 << 10 nM). For lower-affinity antibodies, the choice of assay platform may become more critical .

How can researchers effectively evaluate antibody cross-reactivity against viral variants in a single assay?

Assessing antibody activity against multiple viral variants typically requires separate assays for each variant, which is resource-intensive. Recent research has validated approaches for evaluating activity against variant mixtures.

Methodological approach:
Studies have demonstrated that antibody efficacy against variant mixtures can be predicted when the proportion of the "primary" variant (the one the antibody was designed against) is known:

For SARS-CoV-2 variants, researchers observed that most monoclonal antibodies maintained at least 50% of their activity against pseudovirus mixtures containing Wuhan:Delta and Wuhan:Omicron variants if the mixtures contained ≥46% of the particles expressing the SARS-CoV-2 Wuhan "primary" variant .

This finding enables more efficient screening of antibody efficacy against emerging variants using mixed-variant assays, substantially reducing the resources required for comprehensive variant testing.

How do receptor-binding domain mutations in SARS-CoV-2 variants affect antibody recognition and neutralization?

SARS-CoV-2 variants like Delta and Omicron show differential antibody escape mechanisms related to both antibody specificity and receptor affinity.

Methodological findings:
Research utilizing receptor binding kinetics, anti-RBD titer measurements, and neutralization assays revealed:

• Both Delta and Omicron variants exhibit higher affinity for the ACE2 receptor compared to the original Wuhan strain, facilitating infection .

• This increased receptor affinity contributes to "affinity escape" - a mechanism where higher virus-receptor affinity can outcompete antibody binding even when antibodies recognize the variant.

• For Omicron specifically, the neutralization reduction is more pronounced because it combines:

  • Affinity escape: Higher ACE2 binding affinity

  • Specificity escape: Reduced antibody recognition due to mutations

A comparative study measuring binding kinetics using Octet RED96E (Sartorius) revealed significant differences:

These findings explain why serum from vaccinated individuals shows reduced neutralization capability against variants, particularly Omicron, despite the presence of antibodies that still bind to the RBD .

What role do T cell responses play in conjunction with antibody responses in viral protection, and how can this inform vaccine design?

While antibody responses have received significant attention, T cell responses are increasingly recognized as crucial components of immunity against viruses like SARS-CoV-2.

Research findings and methodological implications:

• T cell responses reduce disease severity while improving B cell maturation and production of neutralizing antibodies .

• Unlike antibodies that primarily target the spike protein, T cells can recognize a broader range of epitopes across viral proteins, making immune escape less likely .

• Even with variants like Omicron where antibody neutralization is reduced, T cell responses can provide important protection, though they too show some reduction in recognizing mutated spike epitopes .

This understanding has important methodological implications for vaccine design:

Novel vaccine approach - TOH-VAC-2:
Researchers have developed a T cell-targeted multi-antigen vaccine that generates:

• High titers of S- and N-specific antibodies

• Robust T cell immunity against S, N, and poly-epitope antigens

The approach involves strategically designing a poly-epitope antigen using immunodominant epitopes that:

• Stimulate both CD4 and CD8 T cells

• Are highly conserved across known variants of concern

• Are derived from many different viral proteins, reducing the likelihood of escape mutations

For researchers designing next-generation vaccines, this approach offers greater resilience against emerging variants by targeting conserved regions across multiple viral proteins rather than focusing solely on the more mutable spike protein.

What are the characteristics and functions of infection-enhancing antibodies directed to the NTD of SARS-CoV-2, and how can researchers distinguish them from neutralizing antibodies?

The existence of infection-enhancing antibodies raises important questions about their impact on disease progression and vaccine design.

Research findings:
Recent studies have identified antibodies that can enhance SARS-CoV-2 infection in vitro through Fcγ-receptor (FcγR)-independent mechanisms. These antibodies:

• Recognize NTD epitopes outside the neutralization supersite

• Are adjacent to the NTD variable loops

Importantly, these antibodies may have dual functions:

• They can enhance infection in certain in vitro assays

• They may also contribute to viral clearance through FcγR-mediated effector functions

Methodological approaches to identify and characterize these antibodies:

• Researchers isolated NTD-binding antibodies from COVID-19 convalescent donors and assessed:

  • Binding to wild-type and variant S proteins

  • Neutralizing vs. enhancing activities

  • FcγR-activating functionality

• The presence of these antibodies as major clonotypes in some subjects was demonstrated through:

  • Serum IgG enrichment using Protein G agarose columns

  • F(ab')2 generation using IdeS protease

  • Affinity columns with NHS-activated agarose resin coupled with recombinant viral proteins

For antibody characterization, researchers combined:

• ELISA and biolayer interferometry for binding specificity

• Flow cytometry with ZE5 cytometer to analyze ACE2 expression

• Secondary cross-adsorbed anti-human Fab-HRP detection with TMB-ELISA substrate

What is the evidence for antibody-dependent enhancement (ADE) with current vaccines against SARS-CoV-2 variants, and how should researchers interpret contradictory data?

Antibody-dependent enhancement (ADE) has been a theoretical concern with SARS-CoV-2 vaccines, particularly as new variants emerge.

Research analysis:
A critical analysis of the evidence shows:

Methodological guidance for researchers:
When evaluating potential ADE:

• Consider both in vitro and in vivo evidence

• Recognize that cell culture models may not reflect in vivo outcomes

• Evaluate epidemiological data alongside laboratory findings

• Be cautious about extrapolating from theoretical models without supporting evidence

This highlights the importance of using multiple methodological approaches when investigating complex immunological phenomena like ADE.

What are the most appropriate methods for characterizing antibody-antigen interactions at different stages of research?

Different methods for measuring antibody-antigen interactions offer distinct advantages depending on the research stage and specific questions being addressed.

Methodological overview:
For comprehensive antibody characterization, researchers should consider multiple complementary techniques:

Recent research demonstrates that for high-affinity antibodies (KD << 10 nM), the IC50 values determined by different neutralization assays were largely equivalent regardless of cell line or pseudovirus backbone used .

Methodological protocol example (from recent research):
For RBD-ACE2 binding kinetics:

• Use Octet RED96E (Sartorius)

• Load SAX sensors with biotinylated ACE2 (25μg/ml)

• Quench with biocytin

• Serially dilute RBD in kinetics buffer

• Perform dissociation in 300s

• Align resulting curves to beginning of association

• Apply a 1:1 model for global fitting

How can advanced mass spectrometry techniques improve epitope mapping for complex antibody-antigen interactions?

Advanced mass spectrometry offers powerful tools for detailed epitope characterization that complement traditional methods.

Methodological approaches:
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS) has emerged as a particularly valuable technique for epitope mapping of complex protein antigens with antibodies. This approach offers:

• Extremely high mass resolution and accuracy for detecting subtle changes in protein structure upon antibody binding

• Ability to map epitopes through hydrogen/deuterium exchange techniques:

  • Solution-phase amide backbone hydrogen/deuterium exchange monitors changes in solvent accessibility

  • Changes in exchange rates identify regions involved in antibody-antigen interaction

• Capability to characterize epitopes in large antigens (95 kDa and above) in complex with antibodies

Practical implementation example:
Research using FT-ICR MS for epitope mapping employed:

• 14.5 Tesla hybrid linear quadrupole ion trap for high resolution

• Solution-phase hydrogen/deuterium exchange to monitor antibody binding

• Comparison of exchange patterns between free antigen and antibody-bound states

This approach provides significantly more detailed structural information about the binding interface than traditional methods and can identify conformational epitopes that are difficult to characterize through other techniques.

What approaches are available for analyzing antibody co-localization and protein interactions in cellular contexts?

Understanding antibody interactions in cellular contexts requires specialized techniques that preserve spatial information.

Methodological approaches:
Recent research has utilized several complementary techniques to study antibody-protein interactions and co-localization:

• Co-immunoprecipitation (Co-IP):

  • Cells are transfected with designated plasmids and lysed with NP40 buffer

  • Lysates are cleared by centrifugation with protein G-bound affine antibodies

  • Proteins are eluted with pH 2.8 elution buffer (50 mM glycine)

  • Western blotting with specific antibodies identifies interaction partners

• GST pulldown assay:

  • GST-fusion proteins are created with the proteins of interest

  • These are used to pull down potential binding partners

  • Direct binding between proteins can be verified

• Confocal microscopy for co-localization:

  • Cells are co-transfected with plasmids encoding tagged proteins (e.g., Flag-RNASEK and HA-tagged viral proteins)

  • Confocal immunofluorescence assay uses cross-adsorbed secondary antibodies:

    • Goat anti-rabbit IgG (H+L) Alexa Fluor 488

    • Goat anti-mouse IgG (H+L) Alexa Fluor 594

  • Co-localization is assessed through overlay of fluorescent signals

These approaches have been successfully used to demonstrate interactions between antibodies and viral structural proteins, showing cytoplasmic co-localization and providing insights into mechanisms of viral entry and immune response.

How can researchers effectively design bispecific antibodies and evaluate their functionality?

Bispecific antibodies (BsAbs) represent an important frontier in antibody engineering, offering the ability to simultaneously target two different antigens.

Methodological approaches for BsAb design:
Several molecular platforms have been developed for creating bispecific antibodies:

• Orthogonal Fab Interface:

  • Introduces mutations to generate an "orthogonal interface" enabling preferential alignment

  • VRD1 (VL-Q38D VH-Q39K/VL-D1R VH-R62E) and CRD2 (CL-L135Y S176W/CH1-H172A F174G) mutations in one antibody

  • VRD2 (VL-Q38R VH-Q39Y) mutation in another antibody

  • Reduces light chain mismatches and enables stable expression in mammalian cells

• Controlled Fab-arm Exchange (cFAE):

  • Core technology of the Duobody platform

  • Promotes Fab-arm exchange between two antibodies by introducing K409R and F405L mutation sites in CH3 regions

  • Has been used to develop BsAbs targeting CD3×CD123 for AML and EGFR×c-MET for NSCLC

• DVD-Ig and FIT-Ig:

  • Symmetrical platforms with four antigen binding sites

  • DVD-Ig contains a pair of Fab domains with flexible short peptides connecting variable regions

  • FIT-Ig contains two pairs of Fab domains

  • DVD-Ig has been used for antibodies like ABT122 (IL-7×TNF-α) and ABT165 (DLL4×VEGF)

• SEED Design:

  • Allows efficient generation of AG/GA heterodimers

  • Prevents formation of homodimers between AG and GA

  • Enables preferential alignment of Fab domains with correct assembly

These approaches provide researchers with multiple options for designing bispecific antibodies tailored to specific therapeutic needs and target combinations.